Background. Surgical resection is underutilized for patients with colorectal liver metastases (CLM). Although the causes of underutilization are poorly understood, provider attitudes towards surgical referral may be contributory. We sought to understand medical oncologists' perspectives on referral for CLM. Methods. Medical oncologists who treat colorectal cancer in the US state of Michigan were surveyed. We characterized respondents' attitudes regarding clinical and tumorrelated contraindications to liver resection for CLM, as well as referral and treatment preferences using case-based scenarios. We then evaluated practice characteristics and treatment preferences between physicians. Results. A total of 112 eligible responses were received (46 % response rate). Nearly 40 % of respondents reported having no liver surgeons in their practice area. Commonly perceived contraindications to liver resection included extrahepatic disease (80.3 %), poor performance status (77.7 %), the presence of [4 metastases (62.5 %), bilobar metastases (43.8 %), and metastasis size [5 cm (40.2 %). Compared with high-referring physicians, low-referring physicians were just as likely to refer a patient with very low recurrence risk (89.3 vs. 98.3 %; p = 0.099), but much less likely to refer a patient with moderate risk (0 vs. 82.8 %; p \ 0.001). High-referring physicians were more likely to consider resection for scenarios consistent with higher recurrence risk (31.0 vs. 10.7 %; p = 0.05).
Methods. Medical oncologists who treat colorectal cancer in the US state of Michigan were surveyed. We characterized respondents' attitudes regarding clinical and tumorrelated contraindications to liver resection for CLM, as well as referral and treatment preferences using case-based scenarios. We then evaluated practice characteristics and treatment preferences between physicians. Results. A total of 112 eligible responses were received (46 % response rate). Nearly 40 % of respondents reported having no liver surgeons in their practice area. Commonly perceived contraindications to liver resection included extrahepatic disease (80.3 %), poor performance status (77.7 %), the presence of [4 metastases (62.5 %), bilobar metastases (43.8 %), and metastasis size [5 cm (40.2 %). Compared with high-referring physicians, low-referring physicians were just as likely to refer a patient with very low recurrence risk (89.3 vs. 98.3 %; p = 0.099), but much less likely to refer a patient with moderate risk (0 vs. 82.8 %; p \ 0.001). High-referring physicians were more likely to consider resection for scenarios consistent with higher recurrence risk (31.0 vs. 10.7 %; p = 0.05).
Conclusions. We found wide variation in surgical referral patterns for CLM. Many felt that bilobar disease and tumor size were contraindications to liver-directed therapy despite a lack of supporting data. These findings suggest an urgent need to increase dissemination of evidence and guidance regarding management for CLM, perhaps through increased specialist participation in tumor boards.
Colorectal cancer is the second leading cause of cancer death in the US, and most deaths are related to metastatic disease. 1, 2 Surgical resection remains an efficacious treatment for colorectal liver metastases (CLM). In selected patients, CLM resection substantially lengthens survival and, in certain cases, can cure patients. [3] [4] [5] Recently, there has been an expansion in the number and utilization of other highly effective treatments, including multi-agent chemotherapy, biologic agents, and a growing complement of liver-directed interventions, such as radiofrequency and microwave ablation. [6] [7] [8] [9] As a result, the definition of resectable metastatic disease continues to evolve, and patients are increasingly being considered eligible for therapy. 7, [10] [11] [12] However, surgical treatment for metastatic colorectal cancer remains underutilized. [13] [14] [15] [16] It is possible that low surgery rates for CLM reflect lack of referral rather than untreatable disease. 15, 17, 18 Medical oncologists provide care for the vast majority of patients with metastatic disease and drive most treatment decisions, including referral for surgical resection. Thus, medical oncologists are the 'gatekeepers' of treatment and referrals for patients with CLM. As treatment decisions become more complex, it is important to understand the motivating factors that underlie a surgical referral. Nonetheless, there are limited data detailing this complex decision-making process.
A deeper understanding of attitudes and practices within the medical oncology community may promote multidisciplinary collaboration and potentially improve care for CLM. In this context, we performed a population-based assessment of medical oncologists' attitudes towards surgical referral for CLM. Using a novel survey created from previously published instruments, 17, 18 we surveyed oncologists who treat colorectal cancer across the US state of Michigan. The objective of this study was to characterize state-wide variation in attitudes towards CLM. In addition, we also assessed physician characteristics and attitudes associated with surgical referral of patients with CLM.
METHODS
We performed a postal survey of medical oncologists in the state of Michigan. Our objectives were to characterize practices and factors influencing surgical referral decision making. Recipients were identified from statewide registries representing over 95 % of practicing oncologists in Michigan. Recipient addresses and practice locations were verified by telephone as needed. We excluded retired physicians, trainees (fellows), and physicians who did not treat colorectal cancer from our analysis.
Survey Development and Implementation
Survey questions (Appendix) were developed using input from surgeons and medical oncologists with expertise in colorectal cancer, as well as previously published surveys on this topic matter. 17, 18 Survey domains included provider experience and practice setting, staging/follow-up practices, access to advanced liver-directed therapies, multidisciplinary cancer conference/tumor board participation, factors considered when referring patients, and treatment preferences for case scenarios (surgery, systemic therapy, liver-directed therapy, palliative treatment) based on a validated CLM recurrence risk score (CLM score). 19, 20 Responses for patient factors and treatment preferences were assessed using 4-or 5-item Likert questions. The survey instrument was pilot tested among liver surgeons and medical oncologists, and iteratively refined. To maximize response rate, we used a modified Dillman technique for survey implementation, which included a cash incentive for participation ($20) . 18, 21, 22 Study data were collected and managed using REDCap electronic data capture tools hosted at the University of Michigan. 23 A random 40 % sample was used to evaluate for and resolve data entry errors. Re-entry verified a high ([99 %) concordance rate between coders.
Statistical Analysis
The primary goal was to determine oncologists' attitudes towards referral and treatment for CLM, while a secondary goal was to determine whether referral practices were associated with particular practice characteristics. To do this, we characterized respondents a priori into two categories ('low-referring' and 'high-referring') based on their approach to patient scenarios. The 'low-referring' group was characterized by responding 'rarely' or 'never' to questions regarding the referral of patients with lower recurrence risk (CLM scores B3). The 'high-referring' group responded they would 'often' or 'always' refer patients with higher recurrence risk (CLM scores C3). Physicians who overlapped categories (n = 12) were excluded from the analysis. Descriptive characteristics and scenario-based responses were compared between groups using Fisher's exact test, Pearson's v 2 tests, or rank-sum tests as appropriate.
To assess the robustness of our findings, we performed sensitivity analyses. In one analyses, we reclassified physicians into low-and high-referring groups using more exclusive criteria. Low-referring physicians were defined as those who would never/rarely refer patients with CLM scores 0-2, and high-referring physicians were defined as those who would often/always refer patients with CLM scores 4 and higher. In another analyses, we stratified respondents according to whether they reported having liver surgeons in their practice area, to see if treatment preferences differed based on the availability of local expertise.
We performed statistical analyses using STATA Release 12 (StataCorp, College Station, TX, USA). Reported p values were two-sided, with statistical significance established at p \ 0.05. The University of Michigan Institutional Review Board approved the survey instrument and study protocol.
RESULTS
The initial mailing included 297 recipients. Fortyseven respondents did not treat colorectal cancer, and six were not medical oncologists, leaving 244 eligible surveys. A total of 112 eligible, complete responses were received for a response rate of 46 %. Respondents were geographically diverse. Table 1 shows the practice characteristics of responding oncologists. The median time of practice duration was 20 years (interquartile range 7-28 years). The majority of respondents practiced in a community-based setting with or without residents (67, 59.8 %), evaluated 11-50 patients/year (66, 58.9 %), and practiced in large-(population [100,000) or medium-sized ([25,000) cities or suburbs (98, 87.5 %). Forty-one (36.6 %) respondents reported having no liver surgeons in their practice area, and 14 (12.5 %) reported having neither liver surgeons nor liver-specialized interventional radiology services in their practice area. The majority (103, 92 %) attended multidisciplinary tumor boards; of these, most (78, 75.7 %) attended on a weekly basis.
Attitudes and beliefs regarding contraindications to liver resection are shown in Table 2 . Few (10, 8.9 %) respondents felt age was often or always a contraindication to liver resection. Of the 12 characteristics surveyed, the most commonly perceived contraindications were extrahepatic disease (90, 80.3 %), poor performance status (87, 77.7 %), and the presence of [4 metastases (70, 62.5 %). Other commonly perceived contraindications to liver resection were prior liver resection (31, 27.7 %), bilobar metastases (49, 43.8 %), and metastasis size [5 cm (45, 40.2 %). Figure 1 shows changes in respondent attitudes towards referral as CLM recurrence risk increased in patient scenarios. In general, as recurrence risk increased, the proportion of physicians who would often or always refer decreased steadily. A higher proportion of respondents would rarely or never refer patients with bilobar (vs. unilobar) disease and a recurrence risk score of 3. At the extremes, 3 (2.7 %) respondents would rarely/never refer patients with a CLM score of 0, while 7 (6.2 %) would often or always refer patients with high CLM recurrence risk (CLM score 4) and evidence of extrahepatic disease.
In our assessment of scenario-based referral and treatment attitudes, 28 physicians would rarely or never refer patients with low CLM recurrence risk (CLM score B3, hereafter referred to as 'low-referring'), and 58 physicians would often or always refer patients with high recurrence risk (CLM score C3, hereafter referred to as 'high-referring'). Practice differences and attitudes regarding liver resection contraindications between groups are shown in Table 3 . Although practice characteristics were largely similar, there were differences between low-referring and high-referring physicians in their attitudes regarding liver resection contraindications. In particular, low-referring physicians were more likely to consider metastasis size [5 cm (60.7 vs. 30.0 %; p = 0.011) and high carcinoembryonic antigen (CEA) level (25.0 vs. 6.9 %; p = 0.034) as contraindications to liver resection. Table 4 shows attitudes regarding CLM resectability and treatment decisions between low-referring and highreferring physicians. As expected, with increasing CLM recurrence risk the likelihood of surgical referral decreased dramatically among low-referring but not high-referring physicians. For example, compared with high-referring physicians, low-referring physicians were as likely to refer a patient with very low recurrence risk (CLM 0) [89.3 vs. 98.3 %; p = 0.099] but much less likely to refer a patient Treatment choices also varied across groups. While both groups were likely to use chemotherapy in all situations, a higher proportion of high-referring physicians considered liver resection as a treatment option, especially at higher risk levels (CLM scores 3 and 4) [ Table 4 ]. For most scenarios, low-referring physicians were more likely to consider a combination of chemotherapy and liver-directed non-surgical interventions than high-referring physicians. For a patient with potentially unresectable disease (CLM score 4 with extrahepatic disease), treatment choices were similar between groups, but high-referring physicians were still more likely to refer such patients for evaluation by a surgeon.
In the sensitivity analysis, fewer respondents were socalled low-referring (N = 16) or high-referring (N = 48) physicians. Practice characteristic differences and perceptions regarding liver contraindications were similar to the primary analysis, with low-referring physicians considering metastasis size [5 cm a liver resection contraindication more frequently than high-referring physicians. There were also similar trends in first treatment choices, with highreferring physicians consistently more likely to consider liver resection across various recurrence risk scores. When stratified by availability of liver surgeons, the two groups were largely similar with regard to practice characteristics, liver resection contraindications, referral likelihood, and treatment choices.
DISCUSSION
In this state-wide survey of medical oncologists, we found broad variation in attitudes regarding CLM management. A significant proportion of respondents practiced in areas without surgeons with liver expertise. Many considered metastasis size (40.2 %) or bilaterality (43.8 %) to be contraindications for resection. Between low-and highreferring physicians, there were strikingly different management preferences for similar patients. Together, these results imply a lack of knowledge diffusion of modern CLM resectability criteria, 10 and that important treatment decisions for such patients may not include input from liver-directed treatment specialists.
Although the medical literature is replete with studies showing improved cancer outcomes for patients who undergo liver resection for CLM, [3] [4] [5] surgery remains underutilized. [14] [15] [16] The current study adds to our understanding of the reasons many CLM patients are not referred for surgical consideration. A few other studies have suggested physician practice characteristics and attitudes towards CLM resection vary. 17, 18 The present study goes further by highlighting regional variation in CLM management using a state-wide sample of oncologists with diverse practice settings. Importantly, we have identified potential barriers to optimal care, including variability in provider knowledge of resectability criteria.
Many respondents considered bilaterality and metastasis size to be contraindications to liver resection. Moreover, attitudes regarding metastasis size as a resection contraindication differed between low-and high-referring physicians. This suggests an overreliance on prognostic tools such as the CLM clinical risk score 20 to drive surgical referral decision making, which may translate into undertreatment in certain cases. For example, Jones and colleagues 24 demonstrated up to 30 % of patients considered unresectable and managed with palliative chemotherapy actually had potentially resectable disease. These findings are concerning in light of recent evidence demonstrating improved survival after multimodality treatment and complete disease resection, even for patients with poor prognostic scores. For example, Tomlinson et al. 5 demonstrated that even patients with very high recurrence risk scores could be cured if their metastatic disease was completely resected in addition to chemotherapy. Similarly, Nathan et al. 25 demonstrated high conditional survival rates for patients with surgically resected disease, including those with poor predicted prognoses. Consequently, the present study may imply the need for greater specialist input to ensure all available modalities are considered. The need for multidisciplinary collaboration in CLM management has never been higher. Liver resection eligibility criteria have expanded. 10 At the same time, the effectiveness of non-surgical treatment options has improved. 26 For example, modern chemotherapy regimens have permitted longer life expectancy and a greater chance for converting CLM to resectable lesions. [27] [28] [29] Despite this, there remains a lack of strong consensus on optimal treatment patterns, which increases the likelihood of variation in care. 30 Variation in referral practices was not associated with different practice settings. As shown in the present study, the practice settings, locations, and patient volume between low-and high-referring physicians were nearly identical. Rather, the decision to refer seems heavily dependent on provider attitudes towards CLM in general. Supporting this premise are the observed variation in respondent referral thresholds for patients of similar recurrence risk, variation in treatment preferences associated with different referral preferences, and a lack of influence of nearby liver specialists.
These observed differences in treatment preferences are especially interesting given respondents' high rates of attendance and patient presentation at tumor boards. One explanation of these findings is that surgeons may not always attend tumor boards. As a result, respondents may be less likely to consider surgical resection. 31 On the other hand, these findings could represent a failure on the surgeon's part to increase awareness of resection criteria and surgical outcomes as it is unknown to what extent these guidelines and data are known in the general community. In either case, there is a clear need to improve communication to facilitate familiarity with and/or access to updated knowledge of resection eligibility. A key step toward improving access to extirpative treatment in Michigan will be ensuring the dissemination of newer evidence and guideline-supported treatment decisions at multidisciplinary case conferences.
There are several important limitations to this study. First, we could not determine the degree to which a provider's reported attitudes and treatment preferences were associated with their actual practice and why such referral patterns exists. However, the focus of the study was to identify potential barriers to surgical referral, not actual referral rates. Second, survey responses are influenced by individual recall and may be biased towards ideal practice. However, a strength of our study is its broad representation of state-wide oncologists and reasonable survey response rate (46 %), although generalizability of the findings to national patterns of care may be somewhat limited, especially if the distribution and availability of liver specialists are different. Similarly, the results of the present study suggest a high degree of variation in decision making and are congruent with other work. 17, 18, 32 Results were also not substantially changed in sensitivity analyses. Differences in referral patterns are likely to be multifactorial and highly related to beliefs about indications for liver resection as well as the availability of systemic treatment options. Third, we could not assess the degree to which reported tumor board practices represented institutions' true practices. Further research regarding tumor board composition, attendance, and content will be essential to further understanding and improving barriers to knowledge dissemination.
CONCLUSIONS
A survey of medical oncologists in Michigan uncovered broad variation in referral practices and management preferences for CLM. Moreover, it revealed that many oncologists hold certain tumor characteristics to be contraindications to liver-directed therapy, even though such factors are no longer considered contraindications by most liver specialists. Given the high self-reported attendance rates at multidisciplinary tumor boards, these findings imply an urgent need to increase dissemination of evidence and guidance regarding liver-directed management for CLM. To accomplish this, it will be imperative to share these results and directly identify causes for variation in referral patterns related to resection for CLM. First steps may include broader surgical and specialist participation in tumor boards. 31 Decision-support tools, which have been shown to be effective in other populations, may also play a role in this setting. 33 However, increasing dialogue in geographically remote areas may require different strategies. Interventions in these settings could include treatment pathways for CLM or use of telemedicine for tumor board discussions. 34 These findings suggest a need to increase awareness of CLM management options and increase effective dialogue across the many specialties that care for these patients.
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